Primary ovarian insufficiency. [PDF]
CMAJ, 2023 Brent S, Christakis M, Shirreff L.
europepmc +8 more sources
Best Practice & Research: Clinical Obstetrics & GynaecologyThis chapter provides an up to date review of primary ovarian insufficiency. We address the diagnosis, pathophysiology, presentation, evaluation, treatment, and long term follow up of the disease. We discuss a detailed review of the current literature in
Sopiarz N, Sparzak PB.
europepmc +3 more sources
Breast Cancer Is Increased in Women With Primary Ovarian Insufficiency.
J Clin Endocrinol MetabContext DNA damage/repair gene variants are associated with both primary ovarian insufficiency (POI) and cancer risk. Objective We hypothesized that a subset of women with POI and family members would have increased risk for cancer.
Allen-Brady K +11 more
europepmc +2 more sources
Identifying therapeutic targets for primary ovarian insufficiency through integrated genomic analyses. [PDF]
J Ovarian ResPrimary ovarian insufficiency (POI) is a disorder characterized by the premature decline in ovarian function, leading to significant fertility and health impacts on women under 40.
Du H, Zeng P, Liu X, Zhang J, Huang Z.
europepmc +2 more sources
Primary Ovarian Insufficiency, Bone Health, and Other Outcomes in Adolescents. [PDF]
Obstet Gynecol Clin North AmAdolescents with primary ovarian insufficiency (POI) frequently present with arrested pubertal development or amenorrhea. Early evaluation of menstrual irregularities can avoid a delayed diagnosis.
Cipres DT, Gordon CM.
europepmc +2 more sources
Model construction and drug therapy of primary ovarian insufficiency by ultrasound-guided injection. [PDF]
Stem Cell Res TherClinically, hormone replacement therapy (HRT) is the main treatment for primary ovarian insufficiency (POI). However, HRT may increase the risk of both breast cancer and cardiovascular disease.
Dai F +14 more
europepmc +2 more sources
Genetic etiology of primary premature ovarian insufficiency
Acta Clinica Croatica, 2016 Primary premature ovarian insufficiency (PPOI) is characterized by hypergonadotropic amenorrhea and hypoestrogenism in women under 40 years of age. PPOI incidence is 1:10,000 in women aged 18-25, 1:1000 in women aged 25-30 and 1:100 in women aged 35-40 ...
Maja Franić-Ivanišević +6 more
doaj +3 more sources
Primary ovarian insufficiency: an update
International Journal of Women's Health, 2014 Leticia Cox, James H LiuUH Case Medical Center, MacDonald Women's Hospital, Department of Obstetrics and Gynecology, Case Western Reserve University School of Medicine, Department of Reproductive Biology, Cleveland, OH, USAAbstract: Primary ovarian ...
Cox L, Liu JH
doaj +6 more sources
Association of Polymorphisms in FSHR, ESR1, and BMP15 with Primary Ovarian Insufficiency and Meta-Analysis. [PDF]
Diagnostics (Basel)Primary ovarian insufficiency (POI) can lead to menstrual disturbance, resulting in ovarian dysfunction before age 40. Prevalence of POI is usually less than 1%; however, ethnicity or population characteristics may affect prevalence.
Lee JY +9 more
europepmc +2 more sources
Mesenchymal stem cell-derived extracellular vesicles therapy for primary ovarian insufficiency: a systematic review and meta-analysis of pre-clinical studies. [PDF]
J Ovarian ResPrimary ovarian insufficiency (POI) manifests with hormonal imbalances, menstrual irregularities, follicle loss, and infertility. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are emerging as a promising treatment for POI.
Firouzabadi SR +7 more
europepmc +2 more sources